Corrigendum to “Disease-free Survival Analysis for Patients with High-risk Muscle-invasive Urothelial Carcinoma from the Randomized CheckMate 274 Trial by PD-L1 Combined Positive Score and Tumor Cell Score” [Eur. Urol. 83(5) (2024) 432–440] (European Urology (2023) 83(5) (432–440), (S030228382300026X), (10.1016/j.eururo.2023.01.016))
Articolo
Data di Pubblicazione:
2024
Citazione:
Corrigendum to “Disease-free Survival Analysis for Patients with High-risk Muscle-invasive Urothelial Carcinoma from the Randomized CheckMate 274 Trial by PD-L1 Combined Positive Score and Tumor Cell Score” [Eur. Urol. 83(5) (2024) 432–440] (European Urology (2023) 83(5) (432–440), (S030228382300026X), (10.1016/j.eururo.2023.01.016)) / Galsky, M.D., Bajorin, D.F., Witjes, J.A., Gschwend, J.E., Tomita, Y., Nasroulah, F., Li, J., Collette, S., Valderrama, B.P., Grimm, M.-O., Appleman, L., Gravis, G., Necchi, A., Ye, D., Stenner, F., Wind-Rotolo, M., Zhang, J., Unsal-Kacmaz, K.. - In: EUROPEAN UROLOGY. - ISSN 0302-2838. - 85:3(2024), pp. e96-e97. [10.1016/j.eururo.2023.12.013]
Abstract:
The authors regret that there are two errors displayed in Table 1 which require correction. The median age for patients in the CPS <1 group treated with placebo should be corrected to 68.0 years. In addition, the percentage of patients in the CPS <1 group treated with placebo with tumor origin at initial diagnosis of renal pelvis should be corrected to 29%. The corrected table is shown below. The authors would like to apologise for any inconvenience caused.
Tipologia CRIS:
1.1.5. Erratum
Elenco autori:
Galsky, M. D.; Bajorin, D. F.; Witjes, J. A.; Gschwend, J. E.; Tomita, Y.; Nasroulah, F.; Li, J.; Collette, S.; Valderrama, B. P.; Grimm, M. -O.; Appleman, L.; Gravis, G.; Necchi, A.; Ye, D.; Stenner, F.; Wind-Rotolo, M.; Zhang, J.; Unsal-Kacmaz, K.
Link alla scheda completa:
Pubblicato in: